{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:04:11Z","timestamp":1781913851516,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ando.2021.12.001","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:54:31Z","timestamp":1639601671000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Endocrinology of bone mineralization: An update"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6031-4816","authenticated-orcid":false,"given":"A.","family":"Jannin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kerlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Desailloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2021.12.001_bib0355","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00198-019-05174-5","article-title":"Impact of osteoporotic fracture type and subsequent fracture on mortality: the Troms\u00f8 Study","volume":"31","author":"Alarkawi","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0360","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ar.1092140106","article-title":"Osteoblast and osteoclast precursors in primary cultures of calvarial bone cells","volume":"214","author":"Burger","year":"1986","journal-title":"Anat Rec"},{"key":"10.1016\/j.ando.2021.12.001_bib0365","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ando.2021.12.001_bib0370","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1002\/stem.2474","article-title":"Quiescent bone lining cells are a major source of osteoblasts during adulthood","volume":"34","author":"Matic","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.ando.2021.12.001_bib0375","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jbmr.3038","article-title":"Sclerostin antibody administration converts bone lining cells into active osteoblasts","volume":"32","author":"Kim","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0380","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature02040","article-title":"Osteoblastic cells regulate the haematopoietic stem cell niche","volume":"425","author":"Calvi","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ando.2021.12.001_bib0385","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.clinbiochem.2012.03.021","article-title":"An overview of the regulation of bone remodelling at the cellular level","volume":"45","author":"Kular","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ando.2021.12.001_bib0390","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jcb.240550303","article-title":"Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone","volume":"55","author":"Parfitt","year":"1994","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ando.2021.12.001_bib0395","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2021.12.001_bib0400","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia\u00a0\u2013\u00a0aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2021.12.001_bib0405","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jbmr.195","article-title":"Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification","volume":"26","author":"Yadav","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0410","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bone.2017.03.003","article-title":"The role of the progressive ankylosis protein (ANK) in adipogenic\/osteogenic fate decision of precursor cells","volume":"98","author":"Minashima","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.ando.2021.12.001_bib0415","doi-asserted-by":"crossref","first-page":"e1008884","DOI":"10.1371\/journal.pgen.1008884","article-title":"The membrane protein ANKH is crucial for bone mechanical performance by mediating cellular export of citrate and ATP","volume":"16","author":"Szeri","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ando.2021.12.001_bib0420","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.beem.2018.05.009","article-title":"Hypocalcaemic and hypophosphatemic rickets","volume":"32","author":"Lambert","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.12.001_bib0425","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncpneph0124","article-title":"Hypophosphatemia: an evidence-based approach to its clinical consequences and management","volume":"2","author":"Amanzadeh","year":"2006","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ando.2021.12.001_bib0430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2021.12.001_bib0435","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1210\/jcem.86.8.7730","article-title":"X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene","volume":"86","author":"Christie","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.12.001_bib0440","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.12.001_bib0445","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ando.2021.12.001_bib0450","doi-asserted-by":"crossref","first-page":"153892","DOI":"10.1016\/j.metabol.2019.03.009","article-title":"Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)","volume":"103S","author":"Rothenbuhler","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ando.2021.12.001_bib0455","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00784-015-1425-4","article-title":"Review of the dental implications of X-linked hypophosphataemic rickets (XLHR)","volume":"19","author":"Sabandal","year":"2015","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.ando.2021.12.001_bib0460","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2021.12.001_bib0465","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2021.12.001_bib0470","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.12.001_bib0475","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0480","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ando.2021.12.001_bib0485","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00223-021-00843-2","article-title":"Epidemiology of tumor-induced osteomalacia in Denmark","volume":"109","author":"Abrahamsen","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0490","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s00259-018-3971-x","article-title":"Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET\/CT for detecting osteomalacia-associated tumours","volume":"45","author":"Paquet","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ando.2021.12.001_bib0495","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-OR13-1","article-title":"OR13-1 Burosumab improves the biochemical, skeletal, and clinical symptoms of tumor-induced osteomalacia syndrome","volume":"3","author":"Jan De Beur","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2021.12.001_bib0500","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0505","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/archpedi.1948.02030020840003","article-title":"Hypophosphatasia; a new developmental anomaly","volume":"75","author":"Rathbun","year":"1948","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.ando.2021.12.001_bib0510","first-page":"380","article-title":"Hypophosphatasia","volume":"10","author":"Rockman-Greenberg","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.ando.2021.12.001_bib0515","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1359\/jbmr.2001.16.9.1724","article-title":"Hypophosphatasia: molecular diagnosis of Rathbun's original case","volume":"16","author":"Mumm","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0520","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1297-319X(00)00238-4","article-title":"Adult hypophosphatasia. Current aspects","volume":"68","author":"Wendling","year":"2001","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ando.2021.12.001_bib0525","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.berh.2007.11.003","article-title":"Hypophosphatasia","volume":"22","author":"Mornet","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ando.2021.12.001_bib0530","doi-asserted-by":"crossref","first-page":"115795","DOI":"10.1016\/j.bone.2020.115795","article-title":"Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic","volume":"144","author":"Desborough","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.ando.2021.12.001_bib0535","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bone.2013.01.024","article-title":"Clinical spectrum of hypophosphatasia diagnosed in adults","volume":"54","author":"Berkseth","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.ando.2021.12.001_bib0540","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00198-020-05345-9","article-title":"Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment","volume":"31","author":"Bianchi","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0545","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00198-017-4035-y","article-title":"Mutational and biochemical findings in adults with persistent hypophosphatasemia","volume":"28","author":"McKiernan","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0550","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00198-013-2447-x","article-title":"Acute hypophosphatasemia","volume":"25","author":"McKiernan","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0555","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bonr.2016.08.004","article-title":"Case series: odontohypophosphatasia or missed diagnosis of childhood\/adult-onset hypophosphatasia?\u00a0\u2013\u00a0Call for a long-term follow-up of premature loss of primary teeth","volume":"5","author":"Mori","year":"2016","journal-title":"Bone Rep"},{"key":"10.1016\/j.ando.2021.12.001_bib0560","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","article-title":"Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry","volume":"20","author":"H\u00f6gler","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.ando.2021.12.001_bib0565","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.metabol.2016.07.006","article-title":"Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys","volume":"65","author":"Weber","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ando.2021.12.001_bib0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bonr.2015.10.005","article-title":"Multiple fractures, pain, and severe disability in a patient with adult-onset hypophosphatasia","volume":"4","author":"Braunstein","year":"2016","journal-title":"Bone Rep"},{"key":"10.1016\/j.ando.2021.12.001_bib0575","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/jbmr.1565","article-title":"\u201cAtypical femoral fractures\u201d during bisphosphonate exposure in adult hypophosphatasia","volume":"27","author":"Sutton","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0580","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.1752","article-title":"Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy","volume":"28","author":"Otero","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0585","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1210\/jc.2009-1965","article-title":"Lack of sustained response to teriparatide in a patient with adult hypophosphatasia","volume":"95","author":"Gagnon","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.12.001_bib0590","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1210\/jc.2010-1168","article-title":"Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia","volume":"95","author":"Schalin-J\u00e4ntti","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.12.001_bib0595","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1172\/JCI83731","article-title":"Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia","volume":"127","author":"Seefried","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2021.12.001_bib0600","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021: a new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis","year":"2021","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.ando.2021.12.001_bib0605","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0610","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.ando.2021.12.001_bib0615","doi-asserted-by":"crossref","first-page":"115833","DOI":"10.1016\/j.bone.2020.115833","article-title":"The treatment gap: the missed opportunities for osteoporosis therapy","volume":"144","author":"Fuggle","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.ando.2021.12.001_bib0620","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","article-title":"Fragility fractures in Europe: burden, management and opportunities","volume":"15","author":"Borgstr\u00f6m","year":"2020","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.ando.2021.12.001_bib0625","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.ando.2021.12.001_bib0630","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00223-016-0126-6","article-title":"Sclerostin inhibition in the management of osteoporosis","volume":"98","author":"Appelman-Dijkstra","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0635","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ando.2021.12.001_bib0640","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1759720X18775936","article-title":"The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis","volume":"10","author":"S\u00f8lling","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ando.2021.12.001_bib0645","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.12.001_bib0650","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.12.001_bib0655","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","article-title":"Cardiovascular safety and sclerostin inhibition","volume":"106","author":"Langdahl","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.12.001_bib0660","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4158\/EP-2019-0596","article-title":"Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture","volume":"26","author":"Cosman","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2021.12.001_bib0665","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0670","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ando.2021.12.001_bib0675","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2021.12.001_bib0680","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0685","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ando.2021.12.001_bib0690","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-21-0157","article-title":"Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence","volume":"185","author":"Grassi","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2021.12.001_bib0695","doi-asserted-by":"crossref","DOI":"10.1002\/JBMR.4335\/v2\/response1","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ando.2021.12.001_bib0700","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621011082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426621011082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:53:32Z","timestamp":1757717612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426621011082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0003426621011082"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2021.12.001","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrinology of bone mineralization: An update","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2021.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}